316 related articles for article (PubMed ID: 19563463)
41. A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators.
Labrie P; Maddaford SP; Fortin S; Rakhit S; Kotra LP; Gaudreault RC
J Med Chem; 2006 Dec; 49(26):7646-60. PubMed ID: 17181148
[TBL] [Abstract][Full Text] [Related]
42. Identification of polyoxometalates as nanomolar noncompetitive inhibitors of protein kinase CK2.
Prudent R; Moucadel V; Laudet B; Barette C; Lafanechère L; Hasenknopf B; Li J; Bareyt S; Lacôte E; Thorimbert S; Malacria M; Gouzerh P; Cochet C
Chem Biol; 2008 Jul; 15(7):683-92. PubMed ID: 18635005
[TBL] [Abstract][Full Text] [Related]
43. 3D QSAR models built on structure-based alignments of Abl tyrosine kinase inhibitors.
Falchi F; Manetti F; Carraro F; Naldini A; Maga G; Crespan E; Schenone S; Bruno O; Brullo C; Botta M
ChemMedChem; 2009 Jun; 4(6):976-87. PubMed ID: 19326384
[TBL] [Abstract][Full Text] [Related]
44. Structure-based design, synthesis, and study of pyrazolo[1,5-a][1,3,5]triazine derivatives as potent inhibitors of protein kinase CK2.
Nie Z; Perretta C; Erickson P; Margosiak S; Almassy R; Lu J; Averill A; Yager KM; Chu S
Bioorg Med Chem Lett; 2007 Aug; 17(15):4191-5. PubMed ID: 17540560
[TBL] [Abstract][Full Text] [Related]
45. Towards predictive inhibitor design for the EGFR autophosphorylation activity.
San Juan AA
Eur J Med Chem; 2008 Apr; 43(4):781-91. PubMed ID: 17689836
[TBL] [Abstract][Full Text] [Related]
46. 3D-QSAR and molecular docking studies of 1,3,5-triazene-2,4-diamine derivatives against r-RNA: novel bacterial translation inhibitors.
Sekhar YN; Nayana MR; Sivakumari N; Ravikumar M; Mahmood SK
J Mol Graph Model; 2008 Jun; 26(8):1338-52. PubMed ID: 18372201
[TBL] [Abstract][Full Text] [Related]
47. Insight into the structural requirements of proton pump inhibitors based on CoMFA and CoMSIA studies.
Nayana MR; Sekhar YN; Nandyala H; Muttineni R; Bairy SK; Singh K; Mahmood SK
J Mol Graph Model; 2008 Oct; 27(3):233-43. PubMed ID: 18676164
[TBL] [Abstract][Full Text] [Related]
48. Modeling of diarylalkyl-imidazole and diarylalkyl-triazole derivatives as potent aromatase inhibitors for treatment of hormone-dependent cancer.
Nagar S; Saha A
J Comput Chem; 2010 Sep; 31(12):2342-53. PubMed ID: 20340106
[TBL] [Abstract][Full Text] [Related]
49. 3D QSAR studies on 3,4-dihydroquinazolines as T-type calcium channel blocker by comparative molecular similarity indices analysis (CoMSIA).
Jeong JA; Cho H; Jung SY; Kang HB; Park JY; Kim J; Choo DJ; Lee JY
Bioorg Med Chem Lett; 2010 Jan; 20(1):38-41. PubMed ID: 19951839
[TBL] [Abstract][Full Text] [Related]
50. Molecular docking and 3D QSAR studies of Chk2 inhibitors.
Pasha FA; Muddassar M; Joo Cho S
Chem Biol Drug Des; 2009 Mar; 73(3):292-300. PubMed ID: 19207465
[TBL] [Abstract][Full Text] [Related]
51. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
[TBL] [Abstract][Full Text] [Related]
52. Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.
Zhou YJ; Zhu LP; Tang Y; Ye DY
Eur J Med Chem; 2007 Jul; 42(7):977-84. PubMed ID: 17331624
[TBL] [Abstract][Full Text] [Related]
53. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
[TBL] [Abstract][Full Text] [Related]
54. Identification of CK2 inhibitors with new scaffolds by a hybrid virtual screening approach based on Bayesian model; pharmacophore hypothesis and molecular docking.
Di-wu L; Li LL; Wang WJ; Xie HZ; Yang J; Zhang CH; Huang Q; Zhong L; Feng S; Yang SY
J Mol Graph Model; 2012 Jun; 36():42-7. PubMed ID: 22516037
[TBL] [Abstract][Full Text] [Related]
55. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses.
Caballero J; Fernández M; González-Nilo FD
Bioorg Med Chem; 2008 Jun; 16(11):6103-15. PubMed ID: 18468903
[TBL] [Abstract][Full Text] [Related]
56. Rational design based on bioactive conformation analysis of pyrimidinylbenzoates as acetohydroxyacid synthase inhibitors by integrating molecular docking, CoMFA, CoMSIA, and DFT calculations.
He YZ; Li YX; Zhu XL; Xi Z; Niu C; Wan J; Zhang L; Yang GF
J Chem Inf Model; 2007; 47(6):2335-44. PubMed ID: 17887745
[TBL] [Abstract][Full Text] [Related]
57. Molecular modelling studies on d-annulated benzazepinones as VEGF-R2 kinase inhibitors using docking and 3D-QSAR.
Lan P; Sun JR; Chen WN; Sun PH; Chen WM
J Enzyme Inhib Med Chem; 2011 Jun; 26(3):367-77. PubMed ID: 20846090
[TBL] [Abstract][Full Text] [Related]
58. Structural investigation of PAP derivatives by CoMFA and CoMSIA reveals novel insight towards inhibition of Bcr-Abl oncoprotein.
San Juan AA
J Mol Graph Model; 2007 Sep; 26(2):482-93. PubMed ID: 17446106
[TBL] [Abstract][Full Text] [Related]
59. Comparative molecular field analysis of flavonoid inhibitors of the PIM-1 kinase.
Holder S; Lilly M; Brown ML
Bioorg Med Chem; 2007 Oct; 15(19):6463-73. PubMed ID: 17637507
[TBL] [Abstract][Full Text] [Related]
60. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
